Results 61 to 70 of about 17,797 (277)

Pharmacotherapy of irritable bowel syndrome [PDF]

open access: yes, 2017
Irritable bowel syndrome is a group of symptoms that includes abdominal pain and changes in the form and frequency of stool. Since its symptoms are usually long-lasting, the disease significantly degrades quality of life.Several pharmacological therapies
���������
core   +2 more sources

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin   +8 more
wiley   +1 more source

Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor. [PDF]

open access: yes, 2018
The intrinsic efficacy of orthosteric ligands acting at G-protein-coupled receptors (GPCRs) reflects their ability to stabilize active receptor states (R*) and is a major determinant of their physiological effects.
Livingston, Kathryn E   +4 more
core  

Older patients' prescriptions screening in the community pharmacy: development of the Ghent Older People's Prescriptions community Pharmacy Screening (GheOP3S) tool [PDF]

open access: yes, 2015
Background: Ageing of the population often leads to polypharmacy. Consequently, potentially inappropriate prescribing (PIP) becomes more frequent. Systematic screening for PIP in older patients in primary care could yield a large improvement in health ...
Boussery, Koen   +5 more
core   +2 more sources

A case report on the long‐term use of teduglutide in a pediatric patient with short bowel syndrome

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Short bowel syndrome (SBS) is the leading cause of intestinal failure, frequently necessitating long‐term parenteral nutrition (PN). Teduglutide (TED), a glucagon‐like peptide‐2 analog, has demonstrated efficacy in reducing PN dependence in both adults and children. However, long‐term data in pediatric populations remain limited.
Tsuyoshi Sakurai   +8 more
wiley   +1 more source

A case of yogurt central line‐associated bloodstream infection in a child with intestinal failure

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Central line‐associated bloodstream infections (CLABSI) are a significant cause of morbidity in children with intestinal failure (IF). Probiotic therapy is discouraged in patients with IF because of the increased risk of bacteremia with the probiotic organism.
Nasiha Rahim   +6 more
wiley   +1 more source

The Irritable Bowel Syndrome [PDF]

open access: yes, 2009
A 45 year old businessman presents at your clinic with a 2 year history of recurrent abdominal pain, associated with frequent bouts of diarrhoea. The pain is relieved by defaecation, but there is often a feeling of incomplete evacuation.
Zammit, Edward
core  

Regulation of enteric nervous system via sacral nerve stimulation in opioid-induced constipated rats

open access: yesFrontiers in Neuroscience, 2023
ObjectivesSacral nerve stimulation (SNS) has been employed for treating constipation. However, its mechanisms involving enteric nervous system (ENS) and motility are largely unknown.
Liyun Wang   +5 more
doaj   +1 more source

Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria

open access: yesAging Cell, EarlyView.
Combined baricitinib and lonafarnib treatment improved colonic pathology in LmnaG609G/G609G progeria mice by reducing progerin, maintaining epithelial regeneration, mitigating inflammation and senescence, and preserving microbiome composition. ABSTRACT Hutchinson‐Gilford Progeria Syndrome (HGPS) is a fatal genetic disorder caused by progerin, a mutant ...
Moritz Schroll   +4 more
wiley   +1 more source

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

open access: yesBreast, 2023
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for early discontinuation.
Arlene Chan   +21 more
doaj   +1 more source

Home - About - Disclaimer - Privacy